Last edition
News about "Targeted Protein Degradation"
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
Targeted Protein Degradation | 24/11/2025 | By Dineshwori
NEOsphere Join Hands with Kymera Therapeutics for Novel Molecular Glue Target Discovery
NEOsphere Biotechnologies has partnered with Kymera Therapeutics, Inc. focused on unlocking undrugged or poorly drugged disease-causing protein targets that can be only or best addressed by Targeted Protein Degradation.
Targeted Protein Degradation | 15/05/2024 | By Aishwarya | 179
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy